300142.SZ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 08:09):

Stats
Dzisiejszy wolumen	17.55M
Średni wolumen	19.14M
Kapitalizacja rynkowa	23.00B
EPS	CNY0.0600 ( 2023-10-25 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	92.13
ATR14	CNY0.0260 (0.18%)

Wolumen Korelacja

Długi: -0.24 (neutral)

Krótki: -0.60 (weak negative)

Signal:(48.256) Neutral

Walvax Biotechnology Co., Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Walvax Biotechnology Co., Korelacja - Waluta/Towar

0.69
( moderate )

0.70
( moderate )

0.00
( neutral )

0.75
( moderate )

0.00
( neutral )

-0.78
( moderate negative )

Walvax Biotechnology Co., Finanse

Annual	2023
Przychody:	CNY4.08B
Zysk brutto:	CNY3.40B (83.25 %)
EPS:	CNY0.260

FY	2023
Przychody:	CNY4.08B
Zysk brutto:	CNY3.40B (83.25 %)
EPS:	CNY0.260

FY	2022
Przychody:	CNY5.09B
Zysk brutto:	CNY4.48B (88.02 %)
EPS:	CNY0.460

FY	2021
Przychody:	CNY3.46B
Zysk brutto:	CNY3.07B (88.61 %)
EPS:	CNY0.273

Financial Reports:

No articles found.

Walvax Biotechnology Co.,

Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, researches and develops, produces, and sells bio-medicine products in China. The company offers biomedicines, such as vaccines, blood products, and others. It provides Group A, C meningococcal polysaccharide conjugate vaccine for infants below or equal to 2 years preventing diseases, such as cerebrospinal meningitis and septicemia; Group A and C meningococcal polysaccharide vaccine for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium Neisseria meningitidis group A or group C; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis group A, C, Y, and W135. The company also offers haemophilus influenzae type b conjugate vaccine for children from the age of 2 months to 5 years for the prevention of infectious diseases, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, etc. In addition, it provides diphtheria, tetanus, and acellular pertussis combined vaccine for the prevention of diphtheria, tetanus, and pertussis for individuals from the age of 3 months to 6 years; and 23-valent pneumococcal polysaccharide vaccine for children above 2 years old to prevent pneumococcal disease caused by 23 serotypes. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.